Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

1 luglio 2026 aggiornato da: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Factorial Randomized Clinical Trial

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk. However, evidence regarding effective therapeutic strategies for MASLD in T1D remains scarce. Lifestyle modification has shown benefits in obesity and type 2 diabetes, whereas butyrate, a microbiota-derived short-chain fatty acid, has emerged as a potential therapeutic approach because of its anti-inflammatory and metabolic effects. This study aims to evaluate the efficacy of intensive lifestyle modification, butyrate supplementation, or their combination on hepatic steatosis in individuals with T1D and MASLD.

Methods: BEAM-T1D is a factorial, randomized, 6-month, parallel-group, placebo-controlled clinical trial conducted at the Regional University Hospital of Malaga. A total of 200 adults with T1D and MASLD will be randomized (1:1:1:1) to receive: (1) standard lifestyle recommendations plus placebo; (2) intensive lifestyle modification plus placebo; (3) standard lifestyle recommendations plus butyrate; or (4) intensive lifestyle modification plus butyrate. Intensive lifestyle modification includes a hypocaloric Mediterranean diet and promotion of physical activity. Participants randomized to butyrate will receive 2.25 g/day of microencapsulated sodium butyrate. The primary endpoint will be the change in controlled attenuation parameter (CAP) measured by transient elastography (FibroScan®). Secondary outcomes include changes in liver fat content, insulin resistance, metabolic control, body composition, inflammatory markers, gut microbiota composition, and short-chain fatty acid concentrations.

Results: Participant recruitment is expected to begin in October 2025. The study will evaluate the independent and combined effects of butyrate supplementation and intensive lifestyle modification on hepatic steatosis and metabolic outcomes in individuals with T1D and MASLD.

Conclusion: The BEAM-T1D study will provide novel evidence regarding the potential role of butyrate and intensive lifestyle modification in the management of MASLD in T1D. If effective, these interventions could represent feasible and scalable therapeutic strategies for a population with limited evidence-based treatment options.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

200

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age 18-75 years.
  • Type 1 diabetes.
  • MASLD: Defined by a Controlled Attenuation Parameter (CAP) measured by Fibroscan® ≥248 dB/m (40).
  • Signed informed consent.

Exclusion Criteria:

  • History of alcohol consumption > 50 g/day in men or > 30 g/day in women for 3 consecutive months in the last year.
  • Patients with impaired liver function (total bilirubin > 2.0 mg/dL).
  • Hemochromatosis, Wilson's disease, or autoimmune hepatitis.
  • History of cancer (except basal cell carcinoma) in the past 5 years or active cancer of any type.
  • Known infection with HIV, HBV, HCV, or any other infection that may cause liver disease.
  • Severe underlying diseases that, in the investigators' judgment, constitute an exclusion criterion for study participation.
  • Reduced life expectancy.
  • Pregnant or breastfeeding women.
  • Documented history of intolerance/allergy to butyrate.
  • Participation in another clinical trial within 30 days prior to study entry.
  • Inability to comply with scheduled visits.
  • Use of antibiotics, prebiotics, or probiotics (in pharmacological form or as supplements, not as part of usual diet) in the month prior to inclusion in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione fattoriale
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Placebo + Standard lifestyle recommendations
Participants in this group will not undergo any intervention beyond what is routinely performed in clinical practice. This group will receive microencapsulated placebo.
Comparatore placebo: Placebo + Intensive lifestyle modification
Altro: Intensive lifestyle modification (hypocaloric Mediterranean diet and promotion of physical activity)
Participants will be advised to follow a Mediterranean diet, characterized by the use of olive oil as the main source of fat, regular consumption of vegetables, fruits, legumes, and fish, reduced consumption of red meat and processed meats, and elimination of sugar-sweetened beverages, industrial pastries, and confectionery. The Mediterranean diet will include a 30% energy restriction based on estimated energy needs (Harris-Benedict equation). Participants will also be advised to perform ≥150 minutes of moderate-to-vigorous physical activity per week, distributed over at least 3 days, with no more than 2 consecutive days without activity, and to perform 2-3 resistance training sessions per week on non-consecutive days. This group will receive microencapsulated placebo.
Sperimentale: Butyrate
Integratore alimentare: Butyrate
Participants randomized to this group will receive microencapsulated sodium butyrate (MSB). Each sachet contains 750 mg sodium butyrate and 1750 mg triglyceride matrix (total 2,500 mg). Participants will take 3 sachets daily (total daily dose: 2.25 g butyrate): one in the morning, one at midday, and one in the evening.
Sperimentale: Intensive lifestyle modification + butyrate
Integratore alimentare: Intensive lifestyle modification + butyrate

Participants will undergo both intensive lifestyle modification and receive butyrate as described above.

This study will be placebo-controlled: participants not randomized to butyrate will receive placebo sachets identical in size, color, appearance, and taste to the investigational product but without butyrate. Placebo will also be taken three times daily following the same schedule.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in Controlled Attenuation Parameter (CAP) by hepatic elastography (FibroScan®): Controlled Attenuation Parameter (CAP)
Lasso di tempo: Baseline, 3 month and 6 month
Measured in dB/m
Baseline, 3 month and 6 month
Changes in Controlled Attenuation Parameter (CAP) by hepatic elastography (FibroScan®): Liver Stiffness Measurement
Lasso di tempo: Baseline, 3 month and 6 month
Measured in : kPa
Baseline, 3 month and 6 month

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Changes in insulin resistance: eGDR
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/kg/min
Baseline, 3 months and 6 months
Changes in metabolic control: Glucose
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/dl
Baseline, 3 months and 6 months
Changes in metabolic control: HbA1c
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mmol/mol
Baseline, 3 months and 6 months
Changes in metabolic control: Average sensor glucose
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/dl
Baseline, 3 months and 6 months
Changes in metabolic control: Glucose Management Indicator (GMI)
Lasso di tempo: Baseline, 3 months and 6 months
Measured in %
Baseline, 3 months and 6 months
Changes in metabolic control: Time in range (TIR)
Lasso di tempo: Baseline, 3 months and 6 months
Measured in %
Baseline, 3 months and 6 months
Changes in metabolic control: Time Above Range (TAR)
Lasso di tempo: Baseline, 3 months and 6 months
Measured in %
Baseline, 3 months and 6 months
Changes in metabolic control: Time Below Range (TBR)
Lasso di tempo: Baseline, 3 months and 6 months
Measured in minutes or hours
Baseline, 3 months and 6 months
Changes in body composition: Weight
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in body composition: Body mass index (BMI)
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg/m2
Baseline, 3 months and 6 months
Changes in body composition: Muscular area of rectus anterior
Lasso di tempo: Baseline, 3 months and 6 months
Measured in cm2
Baseline, 3 months and 6 months
Changes in body composition: Fat mass
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in body composition: Fat-free mass
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in body composition: Body cellular mass
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in body composition: Skeletical muscle mass
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in body composition: Appendicular skeletal muscle mass
Lasso di tempo: Baseline, 3 months and 6 months
Measured in kg
Baseline, 3 months and 6 months
Changes in blood pressure: Systolic blood pressure
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mmHg
Baseline, 3 months and 6 months
Changes in blood pressure: Diastolic blood pressure
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mmHg
Baseline, 3 months and 6 months
Changes in lipid profile: Total cholesterol
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/dl
Baseline, 3 months and 6 months
Changes in lipid profile: HDL
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/dl
Baseline, 3 months and 6 months
Changes in lipid profile: LDL
Lasso di tempo: Baseline, 3 months and 6 months
Measured in mg/dl
Baseline, 3 months and 6 months
Changes in adipokines: Leptin
Lasso di tempo: Baseline, 3 months and 6 months
Measured in ng/mL
Baseline, 3 months and 6 months
Changes in adipokines: Adiponectin
Lasso di tempo: Baseline, 3 months and 6 months
Measured in μg/mL
Baseline, 3 months and 6 months
Changes in hepatokines: GDF-15
Lasso di tempo: Baseline, 3 months and 6 months
Measured in ng/mL
Baseline, 3 months and 6 months
Changes in hepatokines: FGF-21
Lasso di tempo: Baseline, 3 months and 6 months
Measured in ng/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: IL-10
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: IL-1b
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: IL-6
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: IL-8
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: IL-12
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in inflammatory markers: TNF-α
Lasso di tempo: Baseline, 3 months and 6 months
Measured in pg/mL
Baseline, 3 months and 6 months
Changes in intestinal permeability: Zonuline
Lasso di tempo: Baseline, 3 months and 6 months
Measured in ng/mL
Baseline, 3 months and 6 months
Changes in short-chain fatty acid levels: Butyrate
Lasso di tempo: Baseline, 3 months and 6 months
Measured in μmol/kg
Baseline, 3 months and 6 months
Changes in gut microbiota: phylum, genus, species
Lasso di tempo: Baseline, 3 months and 6 months
Measured in relative abundance, alpha diversity, beta diversity
Baseline, 3 months and 6 months
Change from baseline in Mediterranean Diet Adherence at 3 and 6 months
Lasso di tempo: Baseline, 3 months and 6 months
The 17-item Mediterranean Diet Adherence Questionnaire assesses dietary habits through 17 questions regarding the consumption of traditional Mediterranean diet components (e.g., olive oil, vegetables, fruits, fish). Each item is scored as 0 (does not meet the criterion) or 1 (meets the criterion), with a total score ranging from 0 (minimum score) to 17 (maximum score). Higher scores indicate greater adherence to the Mediterranean diet.
Baseline, 3 months and 6 months
Change from baseline in Physical Activity Level at 3 and 6 months
Lasso di tempo: Baseline, 3 months and 6 months

The Short version of the International Physical Activity Questionnaire (IPAQ) assesses physical activity across three intensities (vigorous, moderate, and walking) over the last 7 days. Total physical activity is calculated as a continuous variable expressed in Metabolic Equivalent of Task minutes per week (MET-minutes/week), summing the duration (minutes/week) of each activity type multiplied by its specific MET value (walking = 3.3, moderate = 4.0, vigorous = 8.0). Higher MET-minutes/week indicate higher levels of physical activity.

Sedentary behavior is assessed by measuing the total time spent sitting during a typical weekday over the last 7 days (including time at work, home, study, or leisure). The score is expressed as total minutes or hours of sitting time per day. Higher values indicate greater sedentary behavior.
Baseline, 3 months and 6 months
Change from baseline in Long-term Physical Activity Patterns at 3 and 6 months
Lasso di tempo: Baseline, 3 months and 6 months
The validated version of the Nurses' Health Study and Health Professionals' Follow-up Study physical activity questionnaire assesses the average time per week spent on specific recreational activities (e.g., walking, jogging, cycling, swimming, running) over a longer recall period. Each activity is assigned a standard MET value based on intensity (the number of METs corresponding to each activity were calculated using the Compendium of Physical Activities). Total activity is computed as the sum of MET-hours per week (MET-hours/week) by multiplying the weekly hours dedicated to each activity by its corresponding MET value. Higher scores reflect greater energy expenditure from physical activity.
Baseline, 3 months and 6 months
Changes in body composition: Height
Lasso di tempo: Baseline, 3 months and 6 months
Measured in cm
Baseline, 3 months and 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 settembre 2026

Completamento primario (Stimato)

15 settembre 2027

Completamento dello studio (Stimato)

15 febbraio 2028

Date di iscrizione allo studio

Primo inviato

24 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

1 luglio 2026

Primo Inserito (Effettivo)

6 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • BEAM-T1D Study

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi